Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R 2 ) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.Read More
You might also be interested in reading Former SEC Chair: Institutional Investors Clearly Want Access to BTC, Approval of Spot Bitcoin ETFs Inevitable.